TrialRheumatology (Oxford, England)2026

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.

Laure Gossec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.